PolyPid (PYPD) Projected to Announce Quarterly Earnings on Wednesday

PolyPid (NASDAQ:PYPD) is expected to be announcing its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to announce earnings of $0.46 per share and revenue of $30.00 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 8:30 AM ET.

PolyPid (NASDAQ:PYPD) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.03. On average, analysts expect PolyPid to post ($0.44) EPS for the current fiscal year and ($0.85) EPS for the next fiscal year.

PolyPid Price Performance

Shares of PolyPid stock opened at $5.46 on Wednesday. PolyPid has a one year low of $3.50 and a one year high of $5.84. The stock’s 50-day moving average is $5.21 and its 200 day moving average is $4.74. The firm has a market cap of $104.18 million, a price-to-earnings ratio of -3.69 and a beta of 1.43.

Analyst Ratings Changes

A number of brokerages have weighed in on PYPD. Craig Hallum set a $12.00 target price on PolyPid in a report on Wednesday, July 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of PolyPid in a report on Friday, September 18th. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price objective on shares of PolyPid in a research report on Tuesday, July 21st. Oppenheimer initiated coverage on shares of PolyPid in a research note on Tuesday, October 27th. They issued an “outperform” rating and a $10.00 price objective for the company. Finally, Wall Street Zen upgraded shares of PolyPid from a “hold” rating to a “buy” rating in a research report on Saturday. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $11.00.

PolyPid Company Profile

PolyPid Ltd. (NASDAQ: PYPD) is a clinical-stage biopharmaceutical company focused on developing locally administered therapies designed to provide controlled and sustained drug release at treatment sites. The company’s technology is intended to maintain therapeutic drug concentrations over extended periods while limiting systemic exposure.

PolyPid’s lead product candidate is D-PLEX100, an investigational formulation based on doxycycline and the company’s proprietary PLEX polymeric matrix.